Taylor Stacy L 4
4 · Adaptive Biotechnologies Corp · Filed Dec 23, 2021
Insider Transaction Report
Form 4
Taylor Stacy L
SVP and General Counsel
Transactions
- Sale
Common Stock
2021-12-22$30.00/sh−15,338$460,140→ 15,036 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-22−10,130→ 5,313 totalExercise: $6.55Exp: 2028-04-24→ Common Stock (10,130 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-22−5,208→ 17,709 totalExercise: $7.80Exp: 2029-04-23→ Common Stock (5,208 underlying) - Exercise/Conversion
Common Stock
2021-12-22$6.55/sh+10,130$66,352→ 25,166 total - Exercise/Conversion
Common Stock
2021-12-22$7.80/sh+5,208$40,622→ 30,374 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021.
- [F2]The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- [F3]The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.